Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marshall Posner

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Cancer|January 9, 2003
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experienceRobert Haddad, A Dimitrios Colevas, Roy Tishler, et al.
Head & Neck|August 18, 2017
Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer DatabaseNeeraja Konuthula, Alfred M Iloreta, Brett Miles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
HER2 expression in salivary gland carcinomas: dependence on histological subtypeBonnie Glisson, A Dimitrios Colevas, Robert Haddad, et al.
The Lancet. Oncology|February 19, 2013
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert Haddad, Anne O'Neill, Guilherme Rabinowits, et al.
Head & Neck|August 11, 2020
Long-term outcomes in patients with recurrent human papillomavirus-positive oropharyngeal cancer after upfront transoral robotic surgeryWilliam Su, Greeshma Rajeev-Kumar, Martin Kang, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2014
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsMatthew D Galsky, Marshall Posner, Randall F Holcombe, et al.
Oral Oncology|June 23, 2015
Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT studyKaren S Anderson, Jennifer E Gerber, Gypsyamber D'Souza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strainsGerald B Pier, Debra Boyer, Michael Preston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot TrialChrisann Kyi, Vladimir Roudko, Rachel Sabado, et al.
Anti-Cancer Drugs|April 2, 2004
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neckJean-Pierre Pignon, Nathalie Syz, Marshall Posner, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Cancer|January 9, 2003
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experienceRobert Haddad, A Dimitrios Colevas, Roy Tishler, et al.
Head & Neck|August 18, 2017
Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer DatabaseNeeraja Konuthula, Alfred M Iloreta, Brett Miles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
HER2 expression in salivary gland carcinomas: dependence on histological subtypeBonnie Glisson, A Dimitrios Colevas, Robert Haddad, et al.
The Lancet. Oncology|February 19, 2013
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trialRobert Haddad, Anne O'Neill, Guilherme Rabinowits, et al.
Head & Neck|August 11, 2020
Long-term outcomes in patients with recurrent human papillomavirus-positive oropharyngeal cancer after upfront transoral robotic surgeryWilliam Su, Greeshma Rajeev-Kumar, Martin Kang, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2014
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsMatthew D Galsky, Marshall Posner, Randall F Holcombe, et al.
Oral Oncology|June 23, 2015
Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT studyKaren S Anderson, Jennifer E Gerber, Gypsyamber D'Souza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strainsGerald B Pier, Debra Boyer, Michael Preston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot TrialChrisann Kyi, Vladimir Roudko, Rachel Sabado, et al.
Anti-Cancer Drugs|April 2, 2004
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neckJean-Pierre Pignon, Nathalie Syz, Marshall Posner, et al.
Pageof 10